Viatris Inc. (VTRS), Thursday announced positive top-line results from VEGA-3, evaluating MR-141 in patients with presbyopia, the progressive loss of the ability to focus on close objects.
The second pivotal Phase 3 trial comprised of 545 patients who were randomized 3:2 to receive either MR-141 or placebo, once daily in the evening.
The findings showed that patients treated in the MR-141 arm achieved the primary endpoint of Early Treatment Diabetic Retinopathy Study (=3-line) gain in binocular distance-corrected near visual acuity.
Additionally, patients reported satisfaction with near vision upon awakening, satisfaction with their improvement in near vision, and significant improvement in near vision in dim/low light.
Following this, the company expects to apply to the U.S. Food and Drug Administration in second half of 2025.
In the pre-market hours, VTRS is trading at $8.95, up 0.67 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.